Clinical Trials Logo
  1. Home
  2. Healthy
  3. NCT02511691
  4. Details
NCT02511691 Clinical Trial

PET/MRI Imaging of Glutamate Release in the Brain

Healthy Clinical Trial

Official title:
PET/MRI Imaging of Glutamate Release in the Brain of Healthy Controls

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT02511691
Other study ID # KEK ZH 2014-0441
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date July 2015
Est. completion date March 3, 2016

Study information
Verified date August 2020
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Based on PET (18-PSS232) and MRI, glutamate release after N-acetylcystein challenge will be monitored in human brains.

Description:

Diagnostic trial with quantification of glutamate release in PET/MR.

Recruitment information / eligibility
Status Terminated
Enrollment 10
Est. completion date March 3, 2016
Est. primary completion date March 3, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

- healthy volunteer

Exclusion Criteria:

- smoker

- drug addiction

- significant neurological or psychiatric conditions

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• 18F-PSS232
Diagnostic PET Tracer

Locations
Country Name City State
Switzerland University Hopsital Zurich Zurich

Sponsors (1)
Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome
Type Measure Description Time frame Safety issue
Primary Difference of Binding Potentials of 18F-PSS232 in different brain regions between Baseline PET and PET after medical challenge for details, please see Innis: Journal of Cerebral Blood Flow & Metabolism (2007) 27, 1533-1539 Baseline PET and PET after medical challenge will be scanned within 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1